SCPH · Scpharmaceuticals Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $5.01M | $3.47M | - | $3.31M | $2.30M | $1.78M | - | $1.08M | $354.0K | $605.0K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $4.10M | $4.63M | - | $3.54M | $2.68M | $2.73M | - | $3.42M | $2.93M | $2.12M |
| SG&A | $21.23M | $21.41M | - | $21.32M | $17.51M | $17.45M | - | $14.13M | $12.10M | $2.89M |
| Total Operating Expenses | $30.34M | $29.51M | - | $28.17M | $22.48M | $21.96M | - | $9.99M | $15.38M | $7.24M |
| D&A | $4.0K | $4.0K | - | $5.0K | $5.0K | $6.0K | - | $6.0K | $6.0K | $6.0K |
| Operating Income | ($14.29M) | ($17.76M) | - | ($18.15M) | ($14.43M) | ($15.86M) | - | ($14.84M) | ($13.75M) | ($11.55M) |
| Interest Expense | $1.40M | $1.39M | - | $1.85M | $2.13M | $2.10M | - | $2.06M | $2.01M | $1.96M |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($18.02M) | ($19.74M) | - | ($35.10M) | ($17.09M) | ($14.11M) | - | ($15.63M) | ($14.15M) | ($11.21M) |
| EPS - Basic | ($0.34) | ($0.37) | - | ($0.75) | ($0.44) | ($0.36) | - | ($0.41) | ($0.36) | ($0.28) |
| EPS - Diluted | ($0.34) | ($0.37) | - | ($0.75) | ($0.44) | ($0.36) | - | ($0.41) | ($0.36) | ($0.30) |
Balance Sheet
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $40.81M | $57.54M | $75.66M | $91.48M | $38.50M | $58.45M | $46.81M | $35.04M | $71.35M | $75.45M |
| Accounts Receivable | $19.41M | $13.85M | $11.72M | $9.22M | $6.12M | $5.77M | $4.49M | $4.17M | $1.61M | $3.00M |
| Inventory | $14.57M | $14.14M | $13.90M | $18.11M | $15.31M | $9.57M | $8.84M | $7.12M | $5.83M | $3.62M |
| Accounts Payable | $4.03M | $4.99M | $3.88M | $5.00M | $5.29M | $2.71M | $4.00M | $3.37M | $1.18M | $1.63M |
| Current Assets | $78.73M | $89.35M | $105.85M | $123.33M | $62.63M | $76.53M | $92.94M | $104.34M | $113.57M | $126.67M |
| Total Assets | $80.25M | $90.96M | $107.52M | $125.07M | $65.46M | $78.45M | $94.48M | $106.10M | $114.17M | $127.37M |
| Current Liabilities | $20.43M | $16.31M | $14.88M | $15.26M | $12.93M | $12.32M | $13.13M | $10.95M | $6.63M | $7.74M |
| Long-term Debt | $51.20M | $51.05M | $51.35M | $51.10M | $39.99M | $39.38M | $38.81M | $38.26M | $37.74M | $37.25M |
| Total Liabilities | $101.57M | $96.09M | $94.20M | $94.36M | $56.21M | $53.89M | $57.26M | $56.95M | $50.74M | $51.56M |
| Stockholders' Equity | ($21.32M) | ($5.13M) | $13.32M | $30.71M | $9.25M | $24.57M | $37.22M | $49.15M | $63.43M | $75.81M |
| Retained Earnings | ($404.26M) | ($386.24M) | ($366.49M) | ($347.65M) | ($312.54M) | ($295.45M) | ($281.35M) | ($267.53M) | ($251.90M) | ($237.75M) |
Cash Flow
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($17.14M) | - | - | - | ($17.70M) | - | - | - | ($16.49M) |
| Investing Cash Flow | - | - | - | - | - | $29.32M | - | - | - | $7.00M |
| Financing Cash Flow | - | ($972.0K) | - | - | - | $15.0K | - | - | - | $13.70M |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -22.5% | -21.7% | - | -28.1% | -26.1% | -18.0% | - | -14.7% | -12.4% | -8.8% |
| Return on equity | 84.6% | 385.1% | - | -114.3% | -184.8% | -57.4% | - | -31.8% | -22.3% | -14.8% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.85 | 5.48 | 7.12 | 8.08 | 4.84 | 6.21 | 7.08 | 9.53 | 17.12 | 16.38 |
| Quick ratio | 3.14 | 4.61 | 6.18 | 6.89 | 3.66 | 5.44 | 6.40 | 8.88 | 16.24 | 15.91 |
| Cash ratio | 2.00 | 3.53 | 5.09 | 5.99 | 2.98 | 4.74 | 3.56 | 3.20 | 10.75 | 9.75 |
| Leverage | ||||||||||
| Debt / Equity | -2.40 | -9.96 | 3.86 | 1.66 | 4.32 | 1.60 | 1.04 | 0.78 | 0.60 | 0.49 |
| Debt / Assets | 0.64 | 0.56 | 0.48 | 0.41 | 0.61 | 0.50 | 0.41 | 0.36 | 0.33 | 0.29 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -10.2x | -12.8x | - | -9.8x | -6.8x | -7.5x | - | -7.2x | -6.8x | -5.9x |
| Equity multiplier | -3.77 | -17.74 | 8.07 | 4.07 | 7.08 | 3.19 | 2.54 | 2.16 | 1.80 | 1.68 |
| Liabilities / Assets | 1.27 | 1.06 | 0.88 | 0.75 | 0.86 | 0.69 | 0.61 | 0.54 | 0.44 | 0.40 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 0.34 | 0.25 | - | 0.18 | 0.15 | 0.19 | - | 0.15 | 0.06 | 0.17 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 1061d | 1487d | - | 1996d | 2429d | 1957d | - | 2410d | 6013d | 2185d |
| Days payable outstanding | 293d | 525d | - | 552d | 840d | 553d | - | 1140d | 1219d | 981d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 0.9% | -12.0% | - | -22.3% | -5.0% | -37.2% | - | -48.5% | -45.9% | -59.6% |
| Net income growth (YoY) | -5.5% | -39.9% | - | -124.5% | -20.7% | -25.9% | - | -53.8% | -46.0% | -45.0% |
| EPS growth (YoY) | 22.7% | -2.8% | - | -82.9% | -22.2% | -20.0% | - | -10.8% | -2.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -64.2% | -37.5% | -85.4% | -67.6% | -48.6% | 58.0% | 56.8% | 53.5% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing scPharmaceuticals Inc. against the 5 most active filers in the same SIC group.